Assembly Biosciences grants 8,000 options to director

ASSEMBLY BIOSCIENCES, INC. director Michael Houghton received a grant of stock options covering 8,000 shares of common stock.

Accepted by SEC EDGAR 06/05/2026 - 04:40 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ASSEMBLY BIOSCIENCES, INC. director Michael Houghton received a grant of stock options covering 8,000 shares of common stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036. They vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Houghton holds 8,000 stock options directly.

Insider Trade Summary

Grant/Award: 8,000 shares

Grant/Award 1 txn

Insider Houghton Michael

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	8,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 8,000 contracts (Direct)

Footnotes (1)

1. F1. Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders.

Key Figures

Stock options granted: 8,000 options Exercise price: $24.11 per share Expiration date: June 4, 2036 +2 more

5 metrics

Stock options granted 8,000 options Grant to director Michael Houghton

Exercise price $24.11 per share Stock option strike price

Expiration date June 4, 2036 Option term end

Underlying shares 8,000 shares Common stock underlying options

Holdings after grant 8,000 options Total derivative holdings following transaction

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, Common Stock, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

annual meeting of stockholders financial

"the date of the Issuer's 2027 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Assembly Biosciences (ASMB) report for Michael Houghton?

Assembly Biosciences reported that director Michael Houghton received a grant of 8,000 stock options. These options give him the right to buy common shares at a fixed exercise price, functioning as part of his equity-based compensation from the company.

How many stock options did Michael Houghton receive from Assembly Biosciences (ASMB)?

Michael Houghton received 8,000 stock options. Each option relates to one share of Assembly Biosciences common stock, giving him potential future ownership if he chooses to exercise the options at or above the specified exercise price.

What is the exercise price of Michael Houghton’s Assembly Biosciences (ASMB) stock options?

The exercise price of Michael Houghton’s stock options is $24.11 per share. This means he can buy Assembly Biosciences common stock at $24.11, regardless of the future market price, once the options have vested and before they expire.

When do Michael Houghton’s Assembly Biosciences (ASMB) stock options vest?

The options vest upon the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders. Vesting is conditioned on Houghton’s continuous service with Assembly Biosciences through that date, aligning his compensation with ongoing board involvement.

When do Michael Houghton’s Assembly Biosciences (ASMB) stock options expire?

Michael Houghton’s stock options expire on June 4, 2036. After this expiration date, any unexercised options become worthless, so he must exercise vested options before that time to acquire shares at the $24.11 exercise price.

How many Assembly Biosciences (ASMB) options does Michael Houghton hold after this grant?

Following this grant, Michael Houghton holds 8,000 stock options directly. The filing does not show additional derivative holdings, so this grant represents his reported option position in Assembly Biosciences common stock as of the transaction date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Houghton Michael

(Last) (First) (Middle)

C/O ASSEMBLY BIOSCIENCES, INC.

TWO TOWER PLACE, 7TH FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ASSEMBLY BIOSCIENCES, INC. [ ASMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$24.11	06/04/2026		A		8,000		(1)	06/04/2036	Common Stock	8,000	$0	8,000	D

Explanation of Responses:

1. Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders.

	/s/ John O. Gunderson, as Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)